- Availability of Preparatory Documents for the Combined General Meeting of May 15, 2024
- Mise à disposition des documents préparatoires à l'Assemblée générale du 15 mai 2024
- Document d'enregistrement Universel 2023
- MIse à disposition du document d'enregistrement universel 2023 de Transgene
- Availability of Transgene's 2023 Universal Registration Document
- Transgene et NEC présentent les premiers signes de bénéfice clinique de leur vaccin individualisé contre le cancer, TG4050, dans les cancers de la tête et du cou à l’AACR 2024
- Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
- Transgene nomme Lucie Larguier en tant que Directrice Financière et Christelle Schwoerer Comme Directrice des Ressources Humaines
- Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer
- Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025
More ▼
Key statistics
As of last trade, Transgene SA (TGNA:STU) traded at 1.25, 24.21% above the 52 week low of 1.01 set on Feb 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.31 |
---|---|
High | 1.32 |
Low | 1.25 |
Bid | 1.25 |
Offer | 1.31 |
Previous close | 1.30 |
Average volume | 0.00 |
---|---|
Shares outstanding | 100.85m |
Free float | 35.05m |
P/E (TTM) | -- |
Market cap | 135.75m EUR |
EPS (TTM) | -0.2227 EUR |
Data delayed at least 15 minutes, as of Apr 25 2024.
More ▼